Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGD | P52209 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | PGK2 | P07205 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3431354 | 0.88 | PGD (0.39) | PGDPDE4APGK1PGK2 | |
| SCHEMBL1016010 | 0.79 | BTN3A1 (0.33) | — | |
| SCHEMBL11305111 | 0.79 | BTN3A1 (0.33) | — | |
| SCHEMBL9698100 | 0.79 | BTN3A1 (0.33) | — | |
| SCHEMBL29512271 | 0.79 | BTN3A1 (0.33) | — | |
| Glucuronic Acid SCHEMBL27891138 | 0.77 | MPI (0.39) | PGDPDE4APGK1PGK2 | |
| Glucuronic Acid SCHEMBL3696739 | 0.77 | MPI (0.39) | PGDPDE4APGK1PGK2 | |
| SCHEMBL5165444 | 0.77 | LMNA (0.37) | PDE4A | |
| SCHEMBL536484 | 0.77 | LMNA (0.37) | PDE4A | |
| SCHEMBL4082207 | 0.77 | LMNA (0.37) | PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118995702-A | Double-stranded ribonucleic acid for inhibiting UGT1A1 gene expression, and modification, conjugate and application thereof | 北京福元医药股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-11891655-B2 | Probe for selectively characterizing enzymes involved in xenobiotic metabolism and method of making and using the same | BATTELLE MEMORIAL INSTITUTE (US) | 2024-02-06 | — | — | US | disclosed |
| EP-3755339-B1 | 3-BETA-(4-METHOXYBENZYLOXY)PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF CANNABINOIDS-RELATED DISORDERS | AELIS FARMA (FR) | 2024-01-03 | — | — | EP | disclosed |
| EP-3692014-B1 | PROBE FOR SELECTIVELY CHARACTERIZING ENZYMES INVOLVED IN XENOBIOTIC METABOLISM AND METHOD OF MAKING AND USING THE SAME | BATTELLE MEMORIAL INSTITUTE (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230226076-A1 | 3beta-(4-methoxybenzyloxy)pregn-5-en-20-one for use in the treatment of Cannabinoids-Related Disorders | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-07-20 | — | — | US | disclosed |
| US-11345950-B2 | Probe for selectively characterizing enzymes involved in xenobiotic metabolism and method of making and using the same | BATTELLE MEMORIAL INSTITUTE (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3691653-A1 | SULFATED OLIGOSACCHARIDES HAVING ANTI-INFLAMMATORY ACTIVITY | The University Of North Carolina At Chapel Hill (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-3692014-A1 | PROBE FOR SELECTIVELY CHARACTERIZING ENZYMES INVOLVED IN XENOBIOTIC METABOLISM AND METHOD OF MAKING AND USING THE SAME | Battelle Memorial Institute (US) | 2020-08-12 | — | — | EP | disclosed |
| CN-109689048-A | Oxytocin antagonist dosing regimen to promote embryo implantation and prevent miscarriage | 奥布赛瓦股份公司 | 2019-04-26 | — | — | CN | disclosed |
| WO-2019069297-A2 | PROBE FOR SELECTIVELY CHARACTERIZING ENZYMES INVOLVED IN XENOBIOTIC METABOLISM AND METHOD OF MAKING AND USING THE SAME | KILLINGER, BYRAN J. (US) | 2019-04-11 | — | — | WO | disclosed |
| WO-2009051502-A1 | METHODS OF MAINTAINING OR INCREASING GROWTH OR COGNITIVE DEVELOPMENT | HODGKINSON STEVEN CHARLES (NZ) | 2009-04-23 | — | — | WO | disclosed |
| WO-2008092987-A1 | A METHOD FOR IMPROVING THE PHARMACOKINETICS OF DRUGS METABOLIZED BY UGT2B10 | ORION CORPORATION (FI) | 2008-08-07 | — | — | WO | disclosed |
| EP-1893222-A2 | ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS | Merck & Co., Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| CN-1304577-C | Cotton glucuronate transferase and coded gene thereof | UNIV TSINGHUA (CN) | 2007-03-14 | — | — | CN | disclosed |
| WO-2006138163-A2 | ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS | MERCK & CO., INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| CN-1673374-A | Cotton glucuronate transferase and coded gene thereof | UNIV TSINGHUA (CN) | 2005-09-28 | — | — | CN | disclosed |
| US-20040110954-A1 | Methods of synthesizing phenol-contining compounds | SMITHKLINE BEECHAM CORPORATION | 2004-06-10 | — | — | US | disclosed |
| EP-1383488-A2 | METHODS OF SYNTHESIZING PHENOL-CONTAINING COMPOUNDS | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002079122-A2 | METHODS OF SYNTHESIZING PHENOL-CONTAINING COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-1996040165-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110954-A1 | Methods of synthesizing phenol-contining compounds | COMT, BPHL, PNMT | PGD 266/4885PDE4A 929/4885PGK1 1156/4885 |
| US-11345950-B2 | Probe for selectively characterizing enzymes involved in xenobiotic metabolism and method of making and using the same | CYP2E1, CYP1A1, CYP7A1 | PGD 589/4885PDE4A 1018/4885PGK1 1171/4885 |
| US-11891655-B2 | Probe for selectively characterizing enzymes involved in xenobiotic metabolism and method of making and using the same | CYP2E1, CYP1A1, CYP7A1 | PGD 589/4885PDE4A 1018/4885PGK1 1171/4885 |
| US-20230226076-A1 | 3beta-(4-methoxybenzyloxy)pregn-5-en-20-one for use in the treatment of Cannabinoids-Related Disorders | CNR1, CNR2, CYP17A1 | PGD 614/4885PDE4A 1556/4885PGK1 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.